Anna V. Wojcicki

Anna V. Wojcicki

Auto-generated profile, based on publicly available information

Anna V. Wojcicki

Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Journal of Hepatology
Verified
Journal Article
Closed access
AKAnna K. Kopec
Anna K. Kopec
NJNikita Joshi
Nikita Joshi
HCHolly Cline-Fedewa
Holly Cline-Fedewa
AWAnna V. Wojcicki
Anna V. Wojcicki
JRJessica L. Ray
Jessica L. Ray
JLJames P. Luyendyk
James P. Luyendyk

1 August 2020 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
AWAnna V. Wojcicki
Anna V. Wojcicki
MKMaya M. Kasowski
Maya M. Kasowski
Kathleen SakamotoKathleen Sakamoto
Kathleen Sakamoto
NLNorman James Lacayo
Norman James Lacayo

13 February 2020 in Cancers
Verified
Journal Article
Open access
PDF file
AWAnna V. Wojcicki
Anna V. Wojcicki
MKMeena Kadapakkam
Meena Kadapakkam
AFAdam Frymoyer
Adam Frymoyer
NLNorman James Lacayo
Norman James Lacayo
HCHee-Don Chae
Hee-Don Chae
Kathleen SakamotoKathleen Sakamoto
Kathleen Sakamoto
Acute myeloid leukemia (AML) is a clinically and genetically heterogenous malignancy of myeloid progenitor cells that affects patients of all ages. Despite decades of research and improvement in overall outcomes, standard therapy remains ineffective for certain subtypes of AML. Current treatment is intensive and leads to a number of secondary effects with varying results by patient population. Due to the high cost of discovery and an unmet need for new targeted therapies that are well tolerated, alternative drug development strategies have become increasingly attractive. Repurposing existing drugs is one approach to identify new therapies with fewer financial and regulatory hurdles. In this review, we provide an overview of previously U.S. Food and Drug Administration (FDA) approved non-chemotherapy drugs under investigation for the treatment of AML.